European CHMP recommends approval of bimekizumab (Bimzelx) for the treatment of moderate to severe plaque psoriasis

Bimekizumab is a recombinant humanised IgG1 monoclonal antibody that inhibits IL-17A and IL-17F signalling. It has been shown to result in improvements in the IGA 0/1 and PASI 90 response and to reduce itching, pain and scaling of the skin in patients with plaque psoriasis.

Source:

European Medicines Agency